Sulforaphane inhibits invasion by phosphorylating ERK1/2 to regulate E-cadherin and CD44v6 in human prostate cancer DU145 cells

Peng,Xiaohui; Zhou,Yan; Tian,Hua; Yang,Gaoxiang; Li,Chunliu; Geng,Yang; Wu,Sai; Wu,Wei

doi:10.3892/or.2015.4098

Sulforaphane inhibits invasion by phosphorylating ERK1/2 to regulate E-cadherin and CD44v6 in human prostate cancer DU145 cells

Authors:
- Xiaohui Peng
- Yan Zhou
- Hua Tian
- Gaoxiang Yang
- Chunliu Li
- Yang Geng
- Sai Wu
- Wei Wu
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, P.R. China , Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing, P.R. China
Published online on: July 1, 2015 https://doi.org/10.3892/or.2015.4098
Pages: 1565-1572

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Advanced prostate cancer has highly invasive potential, which may lead to metastasis associated with poor prognosis. Sulforaphane (SFN), abundant in cruciferous vegetables, exhibited effective resistance to carcinogenesis in a variety of tumors. The aim of the present study was to investigate whether SFN inhibited invasion in human prostate cancer cells via sustained activation of ERK1/2 and downstream signaling by an invasion assay, gelatin zymography and western blot analysis. The results showed that SFN inhibited invasion and we characterized the underlying mechanisms in human DU145 prostate cancer cells. SFN (15 µM) changed cell morphology leading to short‑cell pseudopodia which may suppress tumor migration and invasion. The Transwell assay showed that SFN phosphorylated ERK1/2 in a dose- and time-dependent manner and significantly inhibited cell invasion, while the effect was reduced by the ERK1/2 blocker PD98059 (25 µM). Furthermore, these effects contributed to the upregulation of E-cadherin and the downregulation of CD44v6 and were eradicated by PD98059. Western blot analysis and gelatin zymography showed that SFN decreased the expression and activity of MMP-2. Thus, SFN inhibited invasion by activating ERK1/2 to upregulate E-cadherin and downregulate CD44v6, thereby reducing MMP-2 expression and activity. E-cadherin is an invasion inhibitor, while CD44v6 and MMP-2 are invasion promoters. Therefore, SFN is a prospective therapeutic agent that may be used to prevent invasion in prostate cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Chaturvedi S and Garcia JA: Novel agents in the management of castration resistant prostate cancer. J Carcinog. 13:52014. View Article : Google Scholar : PubMed/NCBI
3	Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, Shigdar S, Delprado WJ, Graham PH, Bucci J, et al: CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate. 74:602–617. 2014. View Article : Google Scholar : PubMed/NCBI
4	Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, Kobayashi M and Morita T: External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer. BMC Urol. 14:312014. View Article : Google Scholar : PubMed/NCBI
5	Cohen JH, Kristal AR and Stanford JL: Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst. 92:61–68. 2000. View Article : Google Scholar : PubMed/NCBI
6	Zhang SM, Hunter DJ, Rosner BA, Giovannucci EL, Colditz GA, Speizer FE and Willett WC: Intakes of fruits, vegetables, and related nutrients and the risk of non-Hodgkin's lymphoma among women. Cancer Epidemiol Biomarkers Prev. 9:477–485. 2000.PubMed/NCBI
7	Ambrosone CB, McCann SE, Freudenheim JL, Marshall JR, Zhang Y and Shields PG: Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr. 134:1134–1138. 2004.PubMed/NCBI
8	Dinkova-Kostova AT and Kostov RV: glucosinolates and isothiocyanates in health and disease. Trends Mol Med. 18:337–347. 2012. View Article : Google Scholar : PubMed/NCBI
9	Choi S and Singh SV: Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent. Cancer Res. 65:2035–2043. 2005. View Article : Google Scholar : PubMed/NCBI
10	Talalay P and Fahey JW: Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. J Nutr. 131(Suppl): 3027S–3033S. 2001.PubMed/NCBI
11	Conaway CC, Yang YM and Chung FL: Isothiocyanates as cancer chemopreventive agents: Their biological activities and metabolism in rodents and humans. Curr Drug Metab. 3:233–255. 2002. View Article : Google Scholar : PubMed/NCBI
12	Lenzi M, Fimognari C and Hrelia P: Sulforaphane as a promising molecule for fighting cancer. Cancer Treat Res. 159:207–223. 2014. View Article : Google Scholar
13	Cheung KL and Kong AN: Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J. 12:87–97. 2010. View Article : Google Scholar :
14	Clarke JD, Dashwood RH and Ho E: Multi-targeted prevention of cancer by sulforaphane. Cancer Lett. 269:291–304. 2008. View Article : Google Scholar : PubMed/NCBI
15	Hecht SS: Inhibition of carcinogenesis by isothiocyanates. Drug Metab Rev. 32:395–411. 2000. View Article : Google Scholar
16	Li C, Zhou Y, Peng X, Du L, Tian H, Yang G, Niu J and Wu W: Sulforaphane inhibits invasion via activating ERK1/2 signaling in human glioblastoma U87MG and U373MG cells. PLoS One. 9:e905202014. View Article : Google Scholar : PubMed/NCBI
17	Deschênes-Simard X, Kottakis F, Meloche S and Ferbeyre G: ERKs in cancer: Friends or foes? Cancer Res. 74:412–419. 2014. View Article : Google Scholar : PubMed/NCBI
18	Zhou Y, Hu HY, Meng W, Jiang L, Zhang X, Sha JJ, Lu Z and Yao Y: MEK inhibitor effective against proliferation in breast cancer cell. Tumour Biol. 35:9269–9279. 2014. View Article : Google Scholar : PubMed/NCBI
19	Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS Jr, Dunn GP, Bui JD, Sunwoo JB and Uppaluri R: ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 72:365–374. 2012. View Article : Google Scholar :
20	Lau MT, So WK and Leung PC: Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/akt/mToR and MAPK/ERK signaling in ovarian cancer cells. PLoS One. 8:e590832013. View Article : Google Scholar : PubMed/NCBI
21	Burotto M, Chiou VL, Lee JM and Kohn EC: The MaPK pathway across different malignancies: A new perspective. Cancer. 120:3446–3456. 2014. View Article : Google Scholar : PubMed/NCBI
22	Marshall CJ: Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell. 80:179–185. 1995. View Article : Google Scholar : PubMed/NCBI
23	Wu W, Ginsburg E, Vonderhaar BK and Walker AM: S179D prolactin increases vitamin D receptor and p21 through up-regulation of short 1b prolactin receptor in human prostate cancer cells. Cancer Res. 65:7509–7515. 2005. View Article : Google Scholar : PubMed/NCBI
24	Liu Z, Yu X and Shaikh ZA: Rapid activation of ERK1/2 and AKT in human breast cancer cells by cadmium. Toxicol Appl Pharmacol. 228:286–294. 2008. View Article : Google Scholar : PubMed/NCBI
25	Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, Sheu GT and Hsu SL: Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells. Eur J Pharmacol. 663:17–26. 2011. View Article : Google Scholar : PubMed/NCBI
26	Li Z, Du L, Li C and Wu W: Human chorionic gonadotropin β induces cell motility via ERK1/2 and MMP-2 activation in human glioblastoma U87MG cells. J Neurooncol. 111:237–244. 2013. View Article : Google Scholar
27	Li Z, Li C, Du L, Zhou Y and Wu W: Human chorionic gonadotropin β induces migration and invasion via activating ERK1/2 and MMP-2 in human prostate cancer DU145 cells. PLoS One. 8:e545922013. View Article : Google Scholar
28	Wheelock MJ and Johnson KR: Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol. 19:207–235. 2003. View Article : Google Scholar : PubMed/NCBI
29	Cavallaro U and Christofori G: Cell adhesion and signalling by cadherins and Ig-CaMs in cancer. Nat Rev Cancer. 4:118–132. 2004. View Article : Google Scholar : PubMed/NCBI
30	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
31	Li Q and Mattingly RR: Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Ras-transformed breast epithelial cells. Neoplasia. 10:1444–1458. 2008. View Article : Google Scholar : PubMed/NCBI
32	Bae GY, Choi SJ, Lee JS, Jo J, Lee J, Kim J and Cha HJ: Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer. Oncotarget. 4:2512–2522. 2013.PubMed/NCBI
33	Nagano O, Okazaki S and Saya H: Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. 32:5191–5198. 2013. View Article : Google Scholar : PubMed/NCBI
34	Khan SA, Cook AC, Kappil M, Günthert U, Chambers AF, Tuck AB and Denhardt DT: Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: Novel post-transcriptional, post-translational regulation. Clin Exp Metastasis. 22:663–673. 2005. View Article : Google Scholar
35	Akisik E, Bavbek S and Dalay N: CD44 variant exons in leukemia and lymphoma. Pathol Oncol Res. 8:36–40. 2002. View Article : Google Scholar : PubMed/NCBI
36	Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW and Chen JY: Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44v interaction enhances survival in gastrointestinal cancer cells. Cancer Res. 67:2089–2097. 2007. View Article : Google Scholar : PubMed/NCBI
37	Mulder JW, Wielenga VJ, Polak MM, van den Berg FM, Adolf GR, Herrlich P, Pals ST and Offerhaus GJ: Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis. Gut. 36:76–80. 1995. View Article : Google Scholar : PubMed/NCBI
38	Jones JL and Walker RA: Control of matrix metalloproteinase activity in cancer. J Pathol. 183:377–379. 1997. View Article : Google Scholar
39	Orlichenko LS and Radisky DC: Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis. 25:593–600. 2008. View Article : Google Scholar : PubMed/NCBI
40	Bérubé M, Deschambeault A, Boucher M, Germain L, Petitclerc E and Guérin SL: MMP-2 expression in uveal melanoma: Differential activation status dictated by the cellular environment. Mol vis. 11:1101–1111. 2005.PubMed/NCBI
41	Sato T, Sakai T, Noguchi Y, Takita M, Hirakawa S and Ito A: Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol. 92:47–56. 2004. View Article : Google Scholar : PubMed/NCBI
42	Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Ostör AG, Nie G, Lopata A and Salamonsen LA: Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer. 94:1466–1475. 2002. View Article : Google Scholar : PubMed/NCBI
43	Gupta P, Kim B, Kim SH and Srivastava SK: Molecular targets of isothiocyanates in cancer: Recent advances. Mol Nutr Food Res. 58:1685–1707. 2014. View Article : Google Scholar : PubMed/NCBI
44	Shan Y, Zhang L, Bao Y, Li B, He C, Gao M, Feng X, Xu W, Zhang X and Wang S: Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells. J Nutr Biochem. 24:1062–1069. 2013. View Article : Google Scholar
45	Hahm ER, Chandra-Kuntal K, Desai D, Amin S and Singh SV: Notch activation is dispensable for D, L-sulforaphane-mediated inhibition of human prostate cancer cell migration. PLoS One. 7:e449572012. View Article : Google Scholar : PubMed/NCBI
46	Jo C, Kim S, Cho SJ, Choi KJ, Yun SM, Koh YH, Johnson GV and Park SI: Sulforaphane induces autophagy through ERK activation in neuronal cells. FEBS Lett. 588:3081–3088. 2014. View Article : Google Scholar : PubMed/NCBI
47	Shen KH, Liao AC, Hung JH, Lee WJ, Hu KC, Lin PT, Liao RF and Chen PS: α-Solanine inhibits invasion of human prostate cancer cell by suppressing epithelial-mesenchymal transition and MMPs expression. Molecules. 19:11896–11914. 2014. View Article : Google Scholar : PubMed/NCBI
48	Wu W and Walker AM: Human chorionic gonadotropin beta (HCGbeta) down-regulates E-cadherin and promotes human prostate carcinoma cell migration and invasion. Cancer. 106:68–78. 2006. View Article : Google Scholar
49	Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J and Cheng C: CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 121:1064–1074. 2011. View Article : Google Scholar : PubMed/NCBI
50	Wu G, Zhou Y, Li T, Guo J and Zhou Z: Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma. J Int Med Res. 41:816–824. 2013. View Article : Google Scholar : PubMed/NCBI
51	Yu Q and Stamenkovic I: localization of matrix metal-loproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 13:35–48. 1999. View Article : Google Scholar : PubMed/NCBI
52	Chen Y, Zheng L, Liu J, Zhou Z, Cao X, Lv X and Chen F: Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and RoS/ERK1/2 pathways. Int Immunopharmacol. 21:447–455. 2014. View Article : Google Scholar : PubMed/NCBI
53	Wang Y, Li M, Xu Y, He N, Leng L and Li Z: Tumor necrosis factor-α regulates matrix metalloproteinase-2 expression and cell migration via ERK pathway in rat glomerular mesangial cells. Cell Biol Int. 38:1060–1068. 2014.PubMed/NCBI